Stereotaxis, Inc. Form 10-Q November 09, 2006 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

	FORM 10-Q
X	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For	the quarterly period ended September 30, 2006.
 For	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 the transition period from to
	Commission File Number: 000-50884
	STEREOTAXIS, INC.

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

Delaware (State of Incorporation) 94-3120386 (I.R.S. employer identification no.)

4320 Forest Park Avenue

Suite 100

St. Louis, Missouri (Address of principal executive offices)

63108 (Zip Code)

Edgar Filing: Stereotaxis, Inc. - Form 10-Q

Registrant s telephone number, including area code: (314) 678-6100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes "No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

" Large accelerated filer x Accelerated filer " Non-accelerated filer Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). " Yes x No

The number of outstanding shares of the registrant s common stock on October 31, 2006 was 34,519,958.

STEREOTAXIS, INC.

INDEX TO FORM 10-Q

Part I Financial	Information	Page
Item 1.	Financial Statements (unaudited) Balance Sheets Statements of Operations Statements of Cash Flows Notes to Financial Statements	3 4 5 6-11
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	11-15
Item 3.	Ouantitative and Oualitative Disclosures About Market Risk	16
Item 4.	Controls and Procedures	16
Part II Other In	<u>formation</u>	
Item 1	<u>Legal Proceedings</u>	17
Item 1A.	Risk Factors	17
Item 1B.	<u>Unresolved Staff Comments</u>	17
Item 2.	Issuer Purchases of Equity Securities	17
Item 3.	<u>Defaults upon Securities</u>	17
Item 4.	Submission of Matters to a Vote of Security Holders	17
Item 5.	Other Information	17
Item 6.	Exhibits and Reports on Form 8-K	17
Signature	28	18
Exhibit I	<u>ndex</u>	19

2

ITEM 1. FINANCIAL STATEMENTS

STEREOTAXIS, INC.

BALANCE SHEETS

	Se	September 30,		December 31,	
	(2006 Unaudited)		2005	
Assets	,				
Current assets:					
Cash and cash equivalents	\$	22,629,306	\$	3,598,493	
Short-term investments		17,187,498		7,137,094	
Accounts receivable, net of allowance of \$116,930 and \$29,576 in 2006 and 2005, respectively		12,951,933		5,897,072	
Current portion of long-term receivables		156,927		461,520	
Inventory		9,044,835		9,404,792	
Prepaid expenses and other current assets		2,522,990		5,128,852	
Total current assets		64,493,489		31,627,823	
Property and equipment, net		4,300,087		3,078,313	
Intangible assets, net		1,577,778		1,677,778	
Long-term receivables				146,520	
Other assets		324,006		127,755	
Total assets	\$	70,695,360	\$	36,658,189	
Liabilities and stockholders equity					
Current liabilities:					
Current maturities of long-term debt	\$	833,333	\$	1,000,000	
Accounts payable		3,856,880		4,866,156	
Accrued liabilities		7,661,311		5,648,693	
Deferred contract revenue		7,260,997		4,216,255	
Total current liabilities		19,612,521		15,731,104	
Long-term debt, less current maturities		1,388,889		1,972,222	
Long-term deferred contract revenue		766,494		801,005	
Other liabilities		73,360		28,016	
Stockholders equity:					
Preferred stock, par value \$0.001; 10,000,000 shares authorized at 2006 and 2005, none outstanding at 2006 and 2005					
Common stock, par value \$0.001; 100,000,000 shares authorized at 2006, and 2005; 34,540,388 and					
27,835,611 issued at 2006 and 2005, respectively		34,540		27,836	
Additional paid-in capital		246,814,637		179,286,612	
Deferred compensation				(2,569,760	
Treasury stock, 40,151 and 36,519 shares at 2006 and 2005, respectively		(205,999)		(162,546	
Notes receivable from sales of stock				(180,619	
Accumulated deficit	((197,790,477)	(158,231,069	
Accumulated other comprehensive income (loss)		1,395		(44,612	
Total stockholders equity		48,854,096		18,125,842	
Total liabilities and stockholders equity	\$	70,695,360	\$	36,658,189	

Edgar Filing: Stereotaxis, Inc. - Form 10-Q
See accompanying notes.

3

STEREOTAXIS, INC.

STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended		Nine Months Ended				
		September 30, 2006 2005			September 30, 2006 2005		
Revenue:							
Systems revenue	\$	6,370,082	\$	1,164,570	\$ 10,212,780	\$ 11,257,0	060
Disposables, service and accessories revenue		1,270,231		523,769	2,973,346	1,663,9	906
Total revenue		7,640,313		1,688,339	13,186,126	12,920,9	966
Cost of revenue		3,675,522		791,436	7,089,938	6,426,2	245
Gross margin		3,964,791		896,903	6,096,188	6,494,7	721
Operating expenses:							
Research and development		5,576,769		4,900,054	17,247,408	12,593,4	101
General and administration		4,244,995		4,082,567	12,550,143	10,571,8	
Sales and marketing		5,879,047		3,987,917	16,467,817	11,597,6	
Royalty settlement						2,923,1	
Total operating expenses		15,700,811		12,970,538	46,265,368	37,686,0)87
Operating loss	(11,736,020)	(12,073,635)	(40,169,180)	(31,191,3	366)
Interest income		527,812		228,077	1,638,643	794,0	
Interest expense		(145,365)		(60,737)	(1,028,871)	(180,8	321)
Net loss	\$(11,353,573)	\$ (11,906,295)	\$ (39,559,408)	\$ (30,578,1	134)
Net loss per common share:							
Basic and diluted	\$	(0.34)	\$	(0.44)	\$ (1.21)	\$ (1.	.12)
Weighted average shares used in computing net loss per common share:							
Basic and diluted		33,541,140		27,365,263	32,641,732	27,268,7	772

See accompanying notes.

4

STEREOTAXIS, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

Nine Months Ended

	Septem 2006	ember 30, 2005	
Cash flows from operating activities:		2000	
Net loss	\$ (39,559,408)	\$ (30,578,134)	
Adjustments to reconcile net loss to cash used in operating activities:			
Depreciation	880,841	563,854	
Amortization	552,062	78,592	
Noncash compensation	3,186,943	424,752	
Interest receivable from sale of stock	48,992		
Noncash interest receivable	(2,006)	11,019	
Loss on asset disposal	6,968	46,928	
Changes in operating assets and liabilities:			
Accounts receivable	(7,054,861)	(304,013)	
Long-term receivables	451,113	(421,135)	
Inventories	359,957	(2,914,440)	
Prepaid expenses and other current assets	1,931,549	(636,849)	
Other assets	(196,251)	(1,318)	
Accounts payable	(1,009,276)	2,246,640	
Accrued liabilities	2,012,618	1,995,391	
Deferred contract revenue	3,010,231	844,435	
Other	45,344	9,719	
Net cash used in operating activities Coch flows from investing activities:	(35,335,184)	(28,634,559)	
Cash flows from investing activities:	10.071		
Sale of equipment	10,071	(908,873)	
Purchase of equipment Proceed from the maturity/cele of eveilable for cele investments	(2,119,654)		
Proceeds from the maturity/sale of available-for-sale investments Purchase of available-for-sale investments	16,504,217 (26,287,430)	26,893,000 (8,097,777)	
Furchase of available-for-sale investments	(20,287,430)	(8,097,777)	
Net cash (used in) provided by investing activities	(11,892,796)	17,886,350	
Cash flows from financing activities:			
Payments under long-term debt	(750,000)	(743,767)	
Proceeds from issuance of stock and warrants, net of issuance costs	66,917,546	975,470	
Purchase of treasury stock	(43,453)	,	
Payments received on notes receivable from sale of common stock	134,700		
Net cash provided by financing activities	66,258,793	231,703	
Net increase (decrease) in cash and cash equivalents	19,030,813	(10,516,506)	
Cash and cash equivalents at beginning of period	3,598,493	16,907,516	
Cash and cash equivalents at end of period	\$ 22,629,306	\$ 6,391,010	

See accompanying notes.

STEREOTAXIS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

Basis of Presentation

The accompanying unaudited financial statements of Stereotaxis, Inc. (the Company) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three and nine month periods ended September 30, 2006 are not necessarily indicative of the results that may be expected for the year ended December 31, 2006 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 16, 2006 for the year ended December 31, 2005. Certain prior period amounts have been reclassified to conform to the 2006 presentation.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period as described below.

The Company has deducted shares subject to repurchase and unearned restricted shares from the calculation of shares used in computing net loss per share, basic and diluted. The Company has excluded all outstanding options, stock appreciation rights and warrants from the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. As of September 30, 2006, the Company had 2,487,589 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of \$7.08 per share and 702,696 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of \$8.33 per share. The Company had a weighted average of 572,076 unearned restricted shares excluded from the calculation of net loss per common share for the nine months ended September 30, 2006.

Stock-Based Compensation

Effective January 1, 2006, the Company adopted the fair value recognition provisions of Financial Accounting Standards Board Statement No. 123(R), *Share-Based Payment* (SFAS 123(R)), using the modified prospective transition method to account for its grants of stock options, stock appreciation rights, restricted shares and its employee stock purchase plan. SFAS 123(R) supersedes the provisions of Accounting Principles Board (APB) Opinion No. 25, *Accounting for Stock Issued to Employees* (APB Opinion No. 25) and requires recognition of an expense when goods or services are provided. SFAS 123(R) requires the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. Prior to January 1, 2006, the Company accounted for those plans under the provisions of APB Opinion No. 25, and related interpretations in accounting for stock-based employee compensation as permitted by SFAS 123, *Accounting for Stock-Based Compensation*. Prior to the adoption of SFAS 123(R), stock-based compensation for grants of stock options was included as a pro forma disclosure in the Notes to the Consolidated Financial Statements as permitted by SFAS 123. Results for prior periods have not been restated.

Under the modified prospective transition method of SFAS 123(R), the Company recognized stock-based compensation expense related to 1) the remaining unvested portion of all stock option, stock appreciation right and restricted share awards granted prior to January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS 123; and 2) expense related to all stock option, stock appreciation rights and restricted share awards modified or granted on or subsequent to January 1, 2006, based on the grant date fair value estimated in accordance with the provisions of SFAS 123(R). The Company utilizes the Black-Scholes valuation model to determine the fair value of share-based payments at the date of grant with the following inputs: 1) expected dividend rate of 0%; 2) expected volatility based on the Company s historical volatility and a review of the volatilities of comparable companies; 3) risk-free interest rate based on the Treasury yield on the date of grant and; 4) expected term for grants made subsequent to the adoption of SFAS 123(R) determined in accordance with Staff Accounting Bulletin No. 107 using the simplified method. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company s historical experience and future expectations. Prior to the adoption of SFAS 123(R), the effect of forfeitures on the pro forma

Edgar Filing: Stereotaxis, Inc. - Form 10-Q

expense amounts was recognized as the forfeitures occurred.

6

Stock options or stock appreciation rights issued to non-employees, including individuals for scientific advisory services, are recorded at their fair value as determined in accordance with SFAS 123 and Emerging Issues Task Force (EITF) No. 96-18, *Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction With Selling, Goods or Services,* and recognized over the service period. Deferred compensation for options granted to non-employees is periodically remeasured through the vesting or forfeiture date.

Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Under APB 25, if the shares granted were subject to variable performance criteria, the compensation expense was periodically remeasured through the vesting or forfeiture date.

Shares purchased by employees under the 2004 Employee Stock Purchase Plan are considered to be compensatory and are accounted for in accordance with SFAS 123(R). Under APB Opinion 25, these shares were not considered to be compensatory and were not included in expense but were included in the pro forma expense calculation.

As a result of adopting SFAS 123(R), the Company recorded approximately \$1.1 million and \$3.2 million of share based compensation during the three and nine months ended September 30, 2006. As a result, the Company s net loss for the three and nine month periods ended September 30, 2006 was approximately \$0.3 million and \$1.2 million lower, respectively, than if it had continued to account for share-based compensation under APB Opinion No. 25. Net loss per share for the three and nine month periods ended September 30, 2006 are \$0.01 and \$0.04 lower, respectively than if the Company had continued to account for share-based compensation under APB Opinion No. 25.